IINN News

Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment

Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center

Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation

Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation